Form4insider filings, from the source

SEC Form 4 · accession 0001179110-18-014133

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Michael A. Sherman
Officer — President and CEO · Director
Period of report
Dec 17, 2018
Accepted (ET)
Dec 19, 2018 · 4:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockDec 17, 2018M5,330$2.54A353,248D
Common StockDec 17, 2018M10,035$2.54A363,283D
Common StockDec 17, 2018M15,706$3.82A378,989D
Common StockDec 17, 2018M39,200$9.05A418,189D
Common StockDec 17, 2018M25,002$3.55A443,191D
Common StockDec 17, 2018M11,281$9.86A454,472D
Common StockDec 17, 2018M9,000$11.11A463,472D
Common StockDec 17, 2018M3$5.10A463,475D
Common StockDec 17, 2018M2$3.18A463,477D
Common StockF1Dec 17, 2018G84,112$0.00D379,365D
Common Stockholding———19,919IBy Sherman Investors, LLC

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F2$2.54Dec 17, 2018M5,330D—Mar 5, 2019Common Stock5,3300D
Stock option (right to buy)F2$2.54Dec 17, 2018M10,035D—Nov 12, 2019Common Stock10,0350D
Stock Option (right to buy)F2$3.82Dec 17, 2018M15,706D—Feb 11, 2020Common Stock15,7060D
Stock Option (right to buy)F2$9.05Dec 17, 2018M39,200D—Apr 14, 2021Common Stock39,20020,800D
Stock option (right to buy)F2$3.55Dec 17, 2018M25,002D—Feb 28, 2022Common Stock25,00274,998D
Stock option (right to buy)F2$9.86Dec 17, 2018M11,281D—Feb 19, 2023Common Stock11,28158,719D
Stock option (right to buy)F2$11.11Dec 17, 2018M9,000D—Feb 6, 2024Common Stock9,00036,000D
Stock option (right to buy)F2$5.10Dec 17, 2018M3D—Feb 4, 2025Common Stock386,247D
Stock option (right to buy)F3$3.18Dec 17, 2018M2D—Feb 4, 2026Common Stock286,248D

Explanation of responses